DelveInsight’s, “Opioid Dependence Pipeline Insight 2023” report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in Opioid Dependence pipeline landscape. It covers the Opioid Dependence pipeline drug profiles, including Opioid Dependence clinical trials and nonclinical stage products. It also covers the Opioid Dependence pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Opioid Dependence Pipeline Report

 

• DelveInsight’s Opioid Dependence pipeline report depicts a robust space with 35+ active players working to develop 40+ pipeline therapies for Opioid Dependence treatment.

 

• The leading Opioid Dependence Companies include Opiant Pharmaceuticals, Orexo, Aphios Pharma, DemeRx IB, Inc., Alar Pharmaceuticals, BioXcel Therapeutics, Lyndra Therapeutics, Trevena, Aptinyx, Indivior, Cerevel Therapeutics, BioCorRx, Delpor, AstraZeneca, Gilgamesh Pharmaceuticals, and others

 

• Promising Opioid Dependence Pipeline Therapies include SJP 006, SJP 007, Zolunicant, Naloxone multidose nasal spray, Cannabidiol, Intranasal nalmefene, Morphine extended release, KUR 101, C4X 3256, APH-1501, IVL3004, TRV734, DMX-1002, FP-004, DMX-NB1, DMX-IB1, LYN-014, LYN-013, AZD4041, OX124, OX125, ALA-1000, ALA-1300, ALA-2000, GM-300X, SBS-226, CVL-354, BICX104, KNX100, NYX-783, and others.

 

• The Opioid Dependence Companies and academics are working to assess challenges and seek opportunities that could influence Opioid Dependence R&D. The Opioid Dependence pipeline therapies under development are focused on novel approaches to treat/improve Opioid Dependence.

 

Request a sample and discover the recent breakthroughs happening in the Opioid Dependence Pipeline landscape @ Opioid Dependence Pipeline Outlook Report

 

Opioid Dependence Overview

Opioid dependence is a disorder of regulation of opioid use arising from repeated or continuous use of opioids. The characteristic feature of dependence is a strong internal drive to use opioids, which manifests itself by an impaired ability to control use, increasing priority given to use over other activities, and persistence in use despite harm or negative consequences.

 

Recent Developmental Activities in the Opioid Dependence Treatment Landscape

 

• In December 2022, the US Food and Drug Administration (FDA) accepted the resubmitted New Drug Application (NDA) for Brixadi (buprenorphine) extended-release weekly and monthly subcutaneous injection for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine.

 

• Through a collaboration with the National Institute on Drug Abuse (NIDA), Trevena is developing TRV734 for use in medication-assisted therapy for the treatment of opioid use disorder. Similar to current standard treatment options, it targets the mu receptor, but with an optimized mechanism of action that preferentially engages the signaling pathway responsible for therapeutic effect, with reduced activation of the signaling pathway responsible for mu receptor-mediated adverse effects.

 

• LYN-014, Lyndra’s investigational oral, ultra-long-acting extended-release weekly levomethadone capsule, is being developed for the treatment of people living with opioid use disorder (OUD). The capsule is expected to achieve this through a novel design that will provide extended gastric residence, controlled, steady drug release and timely passage into the gastrointestinal tract. In July 2021, LYN-014 received Fast Track designation (FTD) from the US Food and Drug Administration (FDA).

 

• In November 2022, Aptinyx Inc. announced the finalization of a grant, issued to researchers at Yale University School of Medicine, funding the research and development of NYX-783 for the treatment of OUD. The $5.6 million grant was awarded under the National Institutes of Health (NIH) Helping to End Addiction Long-term (HEAL) Initiative, administered by the National Institute on Drug Abuse (NIDA). The first clinical study funded by the grant will be a randomized, double-blind, placebo-controlled, Phase I drug-drug interaction study to assess the safety, tolerability, and pharmacokinetics of NYX-783 in combination with oxycodone in individuals who use opioids. 

 

For further information, refer to the detailed Opioid Dependence Drugs Launch, Opioid Dependence Developmental Activities, and Opioid Dependence News, click here for Opioid Dependence Ongoing Clinical Trial Analysis

 

Opioid Dependence Emerging Drugs Analysis

 

OX 124: Orexo

OX124 is a powerful naloxone rescue medication, designed to reverse opioid overdoses, including those from highly potent synthetic opioids, such as fentanyl. To meet the target profile for more potent rescue medications, Orexo has developed a novel and unique intranasal formulation technology that allows for rapid and efficient delivery of active ingredients through the intranasal route. Naloxone (OX-124) is under development for the treatment of drug overdose such as opioid overdose. The drug candidate acts by targeting opioid kappa, opioid delta, and opioid Mu receptors. It is administered as a nasal spray. It is developed based on amorphOX technology platform. Currently, the drug in the Preregistration Phase for the treatment of opioid dependence.  

 

APH-1501: Aphios

APH-1501, is an investigational drug being developed by Aphios.APH-1501 belongs to the class of Cannabinoids. It acts as a Cannabinoid receptor modulator. APH-1501, Cannabidiol (CBD), a unique, bioactive component of marijuana, in reducing early attrition and improving outcome in opioid-dependent individual in adults diagnosed with an opioid addiction, ages 21-55 years of age. Currently the drug is in Phase II stage of Clinical trial evaluation for the treatment of Opioid Dependence.

 

DMX-1002: DemeRx IB, Inc.

DMX-1002 is an oral formulation of ibogaine, a naturally occurring psychedelic product isolated from a West African shrub. In previously published non-controlled studies, ibogaine has demonstrated rapid and sustained efficacy in treating OUD and has the potential to be a disease modifying treatment for this vulnerable patient population seeking to end their intractable cycle of drug dependence. DemeRx is developing DMX-1002 for the treatment of OUD. DMX-1002 is a GMP drug product manufactured for human use. Currently the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of Opiate Withdrawal Syndrome.

 

Noribogaine: DemeRx IB, Inc.

NorIbogaine is an indole alkaloid with an atypical opioid pharmacology that may offer unique opportunities to improve the treatment of opioid addiction and to limit tolerance to opioid pain medications.  It is also planned to develop NorIbogaine as a subchronic adjunct therapy to support patients after Ibogaine detoxification who are in early recovery. Noribogaine has pharmacologic properties that distinguish it from methadone, buprenorphine and the major opioid analgesics in clinical use. In animal models of addiction, noribogaine blocks opioid, cocaine, nicotine and alcohol self-administration suggesting that low dose Noribogaine may prove effective as an abstinence-based therapy for opioid and possibly other drug addictions. DemeRx has advanced NorIbogaine in first in human clinical trials. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Opiate Withdrawal Syndrome.

 

Opioid Dependence Pipeline Therapeutics Assessment

There are approx. 35+ key companies which are developing the therapies for Opioid Dependence. The companies which have their Opioid Dependence drug candidates in the most advanced stage, i.e. Preregistration Phase include, Orexo.

 

Find out more about the Opioid Dependence Pipeline Segmentation, Therapeutics Assessment, and Opioid Dependence Emerging Drugs @ Opioid Dependence Treatment Landscape

 

Scope of the Opioid Dependence Pipeline Report

 

• Coverage- Global

 

• Opioid Dependence Companies- Opiant Pharmaceuticals, Orexo, Aphios Pharma, DemeRx IB, Inc., Alar Pharmaceuticals, BioXcel Therapeutics, Lyndra Therapeutics, Trevena, Aptinyx, Indivior, Cerevel Therapeutics, BioCorRx, Delpor, AstraZeneca, Gilgamesh Pharmaceuticals, and others

 

• Opioid Dependence Pipeline Therapies- SJP 006, SJP 007, Zolunicant, Naloxone multidose nasal spray, Cannabidiol, Intranasal nalmefene, Morphine extended release, KUR 101, C4X 3256, APH-1501, IVL3004, TRV734, DMX-1002, FP-004, DMX-NB1, DMX-IB1, LYN-014, LYN-013, AZD4041, OX124, OX125, ALA-1000, ALA-1300, ALA-2000, GM-300X, SBS-226, CVL-354, BICX104, KNX100, NYX-783, and others.

 

• Opioid Dependence Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

 

Dive deep into rich insights for drugs for Opioid Dependence Pipeline Companies and Therapies, click here @ Opioid Dependence Unmet Needs and Analyst Views

 

Table of Content

1. Introduction
2. Executive Summary
3. Opioid Dependence: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Opioid Dependence– DelveInsight’s Analytical Perspective
7. Late Stage Products (Preregistration)
8. OX 124: Orexo
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. APH-1501: Aphios
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Noribogaine: DemeRx IB, Inc.
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. GM-300X: Gilgamesh Pharmaceuticals
18. Inactive Products
19. Opioid Dependence Key Companies
20. Opioid Dependence Key Products
21. Opioid Dependence- Unmet Needs
22. Opioid Dependence- Market Drivers and Barriers
23. Opioid Dependence- Future Perspectives and Conclusion
24. Opioid Dependence Analyst Views
25. Opioid Dependence Key Companies
26. Appendix

 

Got Queries? Find out the related information on Opioid Dependence Mergers and acquisitions, Opioid Dependence Licensing Activities @ Opioid Dependence Recent Trends, and Future Perspectives

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/